Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Progenity

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volume average of 710.93 thousand.

Why Progenity's Stock is Down During Today's Session

The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations

Progenity Reaches Two Million Test Milestone

Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million

Progenity Provides Financial Guidance for Full-year 2021

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced its participation in the 2021 ICR Conference. Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will present a company overview on Thursday, January 14, 2021 at 4 p.m. ET (1 p.m. PT).

Progenity to Present at the 2021 ICR Conference

AnPac Bio-Medical Science Co

Casper Sleep

Phoenix Tree Holdings

Muscle Maker

Lizhi

Velocity Financial

Initial public offerings (IPOs) have been a hot topic of late, with big names like Airbnb and DoorDash having some of the biggest showings this year.

These Are 2020's Biggest IPO Losers

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products in women's health, today announced that it is expanding the availability of COVID-19 RT-PCR testing across the United States to support the rising demand for testing.

Progenity Expands Availability of COVID-19 PCR Testing Services Across United States

Koppers

The RealReal

Adam Johnson of BullseyeBrief.com presented Tuesday at the Benzinga Global Small Cap Conference, discussing his fund of small-cap stock picks on Bullseye Brief, where subscribers can track his trades and analysis. “My whole thing is American ingenuity, the people and companies driving the world forward.

3 Small Cap Stock Picks You've Never Heard Of: Dethroning FAANG With Disruptive Innovation

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the closing of its offering of $85,525,000 aggregate principal amount of 7.25% convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The notes issued today include $10,525,000 principal amount of notes issued pursuant to the partial exercise by the initial purchaser of an option to purchase additional notes.

Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser's Option to Purchase Additional Notes

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the closing of its previously announced underwritten public offering of 7,645,259 shares of its common stock at a public offering price of $3.27 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Progenity, are approximately $25.0 million. All of the shares are being offered by Progenity. Piper Sandler & Co. and Wells Fargo Securities, LLC acted as joint book-running managers for the offering of common stock. BTIG, LLC acted as the lead manager for the offering of common stock.

Progenity Announces Closing of Public Offering of Common Stock

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity also granted the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $15.0 million principal amount of notes.

Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its previously announced underwritten public offering of 7,645,259 shares of its common stock at a public offering price of $3.27 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Progenity, are expected to be approximately $25.0 million. All of the shares are being offered by Progenity. Progenity has granted the underwriters a 30-day option to purchase up to an additional 1,146,788 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 7, 2020, subject to the satisfaction of customary closing conditions. Progenity expects to use the net proceeds from the offering to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform and for working capital and general corporate purposes.

Progenity Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Progenity also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $15 million principal amount of notes.

Progenity Announces Proposed Convertible Senior Notes Offering

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has commenced an underwritten public offering of $25 million of shares of its common stock. In addition, Progenity is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $3.75 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Progenity Announces Proposed Public Offering of Common Stock

High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia

New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020.

Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.

Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will host a Preeclampsia Virtual R&D Day on November 20, 2020 from 11 a.m. to 1 p.m. ET (8 a.m. to 10 a.m. PT). Members of Progenity's senior management team and select guest speakers will provide an in-depth discussion of the company's ongoing clinical development of the Preecludia™ rule-out test for preeclampsia. Attendees will learn about the pathophysiology of preeclampsia, current clinical management and diagnosis of the condition, its health economic burden, and Progenity's diagnostic approach.

Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020

Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS). The DDS capsule uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. Because the DDS localization technology is based on anatomy, it is designed to resist variability in physiological conditions like pH, motility and bacteria.

Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company's Oral Drug Delivery System in Targeting the Colon

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update

Announces Expansion of its COVID-19 Testing Offering

Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone

Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progenity, Inc. (NASDAQ: PROG) ("Progenity" or "the Company") for violations of the federal securities laws.Investors who purchased the Company's shares pursuant to and/or traceable to the Company's June 2020 initial public offering ("IPO") are encouraged to contact the firm before October 27, 2020. ...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Progenity, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to the Company's initial public offering conducted in June 2020 (the "IPO") of the important October 27, 2020 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Progenity investors under the federal securities laws.To join the Progenity class...

PROG Final Deadline Today: Rosen, A Top Ranked Law Firm, Reminds Progenity, Inc. Investors of Important October 27 Deadline in Securities Class Action - PROG

Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO

Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting

New York, New York--(Newsfile Corp. - October 26, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Progenity, Inc. ("Progenity" or "the Company") (NASDAQ: PROG) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Progenity common stock pursuant and/or traceable to the registration statement, as amended (the "Registration Statement"), issued in connection with Progenity's June 2020 initial public offering ("IPO")....

News for Progenity Stock (PROG)